Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Citius Pharmaceuticals Inc

Healthcare US CTXR

0.56USD
-0.0094(1.65%)

Last update at 2026-06-23T20:00:00Z

Day Range

0.550.60
LowHigh

52 Week Range

0.632.48
LowHigh

Fundamentals

  • Previous Close 0.57
  • Market Cap18.91M
  • Volume142329
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-36.35725M
  • Revenue TTM3.94M
  • Revenue Per Share TTM0.27
  • Gross Profit TTM 3.15M
  • Diluted EPS TTM-2.46

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -38.68331M -38.84984M -31.96691M -33.06465M -23.05443M
Minority interest 2.31M 0.29M 0.00000M - -
Net income -37.43391M -39.13884M -32.54291M -33.64065M -23.12519M
Selling general administrative 18.53M 18.25M 21.91M 15.66M 11.29M
Selling and marketing expenses - - - - -
Gross profit -0.21425M -0.20961M -0.19432M - -
Reconciled depreciation 0.21M 0.21M 0.19M 0.18M 0.16M
Ebit -38.41553M -38.84984M -31.96691M -33.31605M -23.53189M
Ebitda -38.20128M -38.64023M -31.77259M -32.88497M -23.04528M
Depreciation and amortization 0.21M 0.21M 0.19M 0.43M 0.49M
Non operating income net other - - - - 0.49M
Operating income -38.52561M -41.99568M -36.73202M -33.31605M -23.53189M
Other operating expenses 38.53M 41.99M 36.73M 33.32M 23.53M
Interest expense 0.27M - - 0.25M 0.01M
Tax provision 1.06M 0.58M 0.58M 0.58M -
Interest income 0.11M 0.76M 1.18M 0.25M 0.26M
Net interest income -0.15770M 0.76M 1.18M 0.25M 0.25M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.06M 0.58M 0.58M 0.58M 0.07M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 38.31M 42.00M 36.73M 33.32M 23.53M
Cost of revenue 0.21M 0.21M 0.19M - -
Total other income expense net -0.15770M 3.15M 4.77M 0.25M 0.48M
Discontinued operations - - - - -
Net income from continuing ops -39.74027M -39.42584M -32.54291M -33.64065M -23.05443M
Net income applicable to common shares - - - -33.64065M -24.50531M
Preferred stock and other adjustments - - - - 1.45M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 130.94M 116.65M 103.61M 114.00M 142.43M
Intangible assets 92.80M 92.80M 59.40M 59.40M 59.40M
Earning assets - - - - -
Other current assets 1.40M 2.70M 7.89M 2.85M 2.74M
Total liab 53.41M 42.55M 12.18M 10.57M 9.65M
Total stockholder equity 67.55M 70.08M 90.83M 102.83M 132.18M
Deferred long term liab - - - 5.56M 4.99M
Other current liab 30.13M 30.40M 2.63M 3.17M 2.53M
Common stock 0.02M 0.00725M 0.16M 0.15M 0.15M
Capital stock 0.02M 0.00725M 0.16M 0.15M 0.15M
Retained earnings -238.80413M -201.37022M -162.23138M -129.68847M -96.04782M
Other liab - - - 5.56M 4.99M
Good will 9.35M 9.35M 9.35M 9.35M 9.35M
Other assets - - - 0.04M 0.04M
Cash 4.25M 3.25M 26.48M 41.71M 70.07M
Cash and equivalents - - - - -
Total current liabilities 44.91M 35.81M 5.78M 4.53M 3.98M
Current deferred revenue - - - - -
Net debt -2.43902M -2.98902M -25.99968M -41.03346M -69.21747M
Short term debt 1.09M 0.48M 0.22M 0.20M 0.18M
Short long term debt 1.00M - - - -
Short long term debt total 1.81M 0.26M 0.48M 0.68M 0.86M
Other stockholder equity 306.34M 271.44M 252.90M 232.37M 228.08M
Property plant equipment - - - 0.00410M 0.00702M
Total current assets 27.93M 14.22M 34.37M 44.56M 72.81M
Long term investments - - - - -
Net tangible assets - - - 102.83M 132.18M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory 22.29M 8.27M - - -
Accounts payable 13.69M 4.93M 2.93M 1.17M 1.28M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - 0.60M 0.60M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - 0.15M 0.15M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -129.68847M -96.04782M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.04M 0.04M 44.95M 39.97M 0.04M
Deferred long term asset charges - - - - -
Non current assets total 103.00M 102.43M 69.24M 69.44M 69.61M
Capital lease obligations 0.81M 0.26M 0.48M 0.68M 0.86M
Long term debt total - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments - -5.00000M 0.00000M 0.00000M -40.00694M
Change to liabilities - - - 0.53M 0.13M
Total cashflows from investing activities -5.75000M -5.00000M - - -40.00694M
Net borrowings 1.30M 0.00000M - - -0.17247M
Total cash from financing activities 33.30M 9.97M 13.83M 0.00000M 120.47M
Change to operating activities - - - 0.35M -2.13813M
Net income -39.74027M -39.42584M -32.54291M -33.64065M -23.05443M
Change in cash 1.00M -23.22905M -15.23076M -28.36126M 56.21M
Begin period cash flow 3.25M 26.48M 41.71M 70.07M 13.86M
End period cash flow 4.25M 3.25M 26.48M 41.71M 70.07M
Total cash from operating activities -26.55274M -28.20137M -29.06021M -28.36126M -24.25041M
Issuance of capital stock 32.30M 13.80M 13.80M 0.00000M 89.43M
Depreciation 0.21M 0.21M 0.19M 0.18M 0.16M
Other cashflows from investing activities -5.75000M -5.00000M - - -40.00000M
Dividends paid - - - - -
Change to inventory -12.64921M -2.13387M 0.00000M - -
Change to account receivables - - - - -
Sale purchase of stock - - - - 120.64M
Other cashflows from financing activities 33.30M -3.83136M 0.03M - 31.21M
Change to netincome - - - 4.48M 1.29M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 40.01M
Change receivables - - - - -0.08800M
Cash flows other operating - - - 0.27M -2.52776M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -28.36126M 56.21M
Change in working capital 1.05M -1.68500M -4.00632M 0.24M -2.71727M
Stock based compensation 10.84M 11.84M 6.62M 3.91M 1.45M
Other non cash items 0.03M 0.28M 0.10M 0.38M 0.07M
Free cash flow -26.55274M -28.20137M -29.06021M -28.36126M -64.25735M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CTXR
Citius Pharmaceuticals Inc		 -0.0094 1.65% 0.56 - 0.51 4.79 0.24 3.30 -2.7425
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Citius Pharmaceuticals Inc

11 Commerce Drive, Cranford, NJ, United States, 07016

Key Executives

Name Title Year Born
Mr. Leonard L. Mazur Co-Founder, CEO, Chairman & Sec. 1945
Mr. Myron Z. Holubiak Co-Founder & Exec. Vice Chairman 1947
Mr. Jaime Bartushak Chief Bus. Officer, CFO & Chief Accounting Officer 1968
Dr. Myron S. Czuczman M.D. Exec. VP & Chief Medical Officer 1960
Mr. Gary F. Talarico Exec. VP of Operations 1955
Ms. Ilanit Allen VP of Investor Relations & Corp. Communications NA
Dr. Alan Lader Ph.D. Sr. VP & Head of Clinical Operations and Quality Assurance NA
Mr. Dhananjay G. Wadekar Sr. VP of Bus. Strategy 1954
Mr. Kelly Creighton Ph.D. Exec. VP of Chemistry, Manufacturing & Controls NA
Mr. Leonard L. Mazur Co-Founder, CEO, Chairman & Secretary 1945

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.